Jeffrey Leiden

Jeffrey Leiden, M.D., Ph.D. is the chairman, president and chief executive officer of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts.[1] He was initially appointed to the board of directors of the company in 2009 and named CEO and president in February 2012.[2][3]

Education

Leiden received his bachelor's degree in biological sciences, a Ph.D. in virology and his M.D. from the University of Chicago.[4] Between 1982 and 1987, Leiden was a clinical fellow in cardiology at the Brigham and Women’s Hospital, the Harvard Medical School and a postdoctoral fellow in medicine at the Dana-Farber Cancer Institute.[5]

Career

in 1987, Leiden was appointed assistant professor of medicine and assistant investigator in the Howard Hughes Medical Institute at the University of Michigan in Ann Arbor.[6] In 1992, Leiden moved to the University of Chicago as the Rawson Professor of Medicine and Pathology and chief of the Division of Cardiology.[7] In 1996, Leiden, along with Drs. Elizabeth and Gary Nabel founded Cardiogene, which was subsequently acquired by Boston Scientific.[8] In 1999, Leiden was appointed the Elkin Blout Professor of Biological Sciences at the Harvard School of Public Health and professor of medicine at the Harvard Medical School.[5] Leiden moved to Abbott Labs in June 2000, as senior vice president and chief scientific officer. Later that year, he was promoted to president and chief operating officer and oversaw all aspects of the company’s global pharmaceutical business, where he developed and launched Kaletra and Humira.[9][10] In 2006, Leiden joined Clarus Ventures as a Managing Director.[11] At Clarus, Leiden founded and chaired the boards of Lycera Corporation and Variation Biotechnologies, and served as Chairman of the Board of TyRx4, Inc., which was subsequently acquired by Medtronic (NYSE: MDT).[12]

Vertex

Leiden has served as chairman, president and chief executive officer of Vertex since 2012. Vertex has since developed and launched Kalydeco, Orkambi and Symdeko - the first medicines to treat the underlying cause of cystic fibrosis.[13][14]

Boards and awards

He is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation and the Association of American Physicians.[15][16] He currently serves as a director of Quest Diagnostics and the Massachusetts Mutual Life Insurance Company, and was the former vice chairman of Shire Pharmaceuticals and a director of Millennium Pharmaceuticals, Abbott Labs and TAP Pharmaceuticals.[5][17] Leiden is also the chairman of the board of PathAI.[18]

In 2017, Ernst and Young named Leiden an Entrepreneur of the Year in Life Sciences.[19] In 2018, the Massachusetts Biotechnology Council awarded Leiden the Henri A. Termeer Innovative Leadership Award.[20]

Leiden also serves as co-chairman of the Massachusetts’s Governor’s Digital Healthcare Council and the Governor’s STEM Advisory Council.[21][22]

Philanthropy

In December 2017, Leiden and his wife Lisa established a professorship in translational medicine at the Brigham and Women’s Hospital and Harvard Medical School.[23] The Leidens are also major donors to the Museum of Fine Arts, Boston, Ariadne Labs and the Bottom Line Foundation.[10][24]

References

  1. ↑ Joe Carlson (December 16, 2011). "Vertex names Leiden incoming CEO". Modern Healthcare.
  2. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals Incorporated's Board of Directors". Biospace. July 8, 2009.
  3. ↑ "Jeffrey "Jeff" Leiden Chairman/President/CEO, Vertex Pharmaceuticals Inc". Bloomberg L.P. Retrieved May 12, 2018.
  4. ↑ Arsenio Oloroso Jr. (September 24, 1994). "Jeffrey M. Leiden Section Chief of Cardiology University of Chicago Medical Center". Crain's Chicago Business.
  5. 1 2 3 "Executive Profile Jeffrey Marc Leiden". Bloomberg L.P. Retrieved May 11, 2018.
  6. ↑ "Putting new muscle into gene therapy". Science. December 6, 1991.
  7. ↑ Emily Mullin. "Jeffrey Leiden--Vertex Pharmaceuticals". FierceBiotech. Retrieved May 10, 2018.
  8. ↑ "Ins and Outs of Cardiovascular Gene Therapy; Cardiogene: The Insuide; Eurogene: The Outside". BioCentury. September 29, 1997.
  9. ↑ "Harvard cardiologist Jeffrey Leiden elected new chief scientific officer at Abbott Laboratories". Medscape. June 16, 2000.
  10. 1 2 "Jeffrey Leiden, M.D., Ph.D." Vertex Pharmaceuticals. Retrieved May 10, 2018.
  11. ↑ "Dr. Jeffrey Leiden Joins Clarus Ventures As Partner". Biospace. November 1, 2006.
  12. ↑ "Jeffrey Leiden M.D., Ph.D. and Dennis Winger Join Vertex Pharmaceuticals' Board of Directors". Evaluate. July 7, 2009.
  13. ↑ Matthew Herper (August 8, 2017). "For Vertex Pharmaceuticals, Can One Billion-Dollar Breakthrough Beget Another?". Forbes.
  14. ↑ "U.S. Food and Drug Administration Approves ORKAMBI for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation". Business Wire. September 28, 2016.
  15. ↑ "Keynote Speakers". Massachusetts Institute of Technology. February 22, 2013.
  16. ↑ Pray, Leslie (August 14, 2007). Understanding the Benefits and Risks of Pharmaceuticals. ISBN 9780309179768.
  17. ↑ "STEM Council Co-Chairs". Massachusetts Department of Higher Education. Retrieved May 20, 2018.
  18. ↑ Alexander Davis (November 2, 2017). "PathAI Raises Series A for AI-Powered Diagnostics". The Wall Street Journal.
  19. ↑ "EY Announces Winners for the Entrepreneur Of The Year® 2017 New England Award". Ernst & Young. June 28, 2017.
  20. ↑ "MassBio to Honor Dr. Jeffrey Leiden with Henri A. Termeer Innovative Leadership Award". MassBio. March 6, 2018.
  21. ↑ "Mass Digital Health Council". Mass Digital Health. Retrieved September 7, 2018.
  22. ↑ "Baker-Polito Administration Appoints STEM Advisory Council for 2017-2018". Mass.gov. Retrieved September 8, 2018.
  23. ↑ "Bench to Bedside". Harvard Medical School. November 1, 2017.
  24. ↑ "The Future is Now: New Investments". Museum of Fine Arts, Boston. Retrieved May 24, 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.